Patents by Inventor Anupong Tangpeerachaikul

Anupong Tangpeerachaikul has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Heteroaromatic macrocyclic ether chemotherapeutic agents
    Patent number: 12275742
    Abstract: Disclosed are heterocyclic heteroaromatic macrocyclic ether compounds, pharmaceutically acceptable salts of the compounds and pharmaceutical compositions thereof. Also disclosed are methods of treating or preventing cancer using the heterocyclic heteroaromatic macrocyclic ether compounds, pharmaceutically acceptable salts of the compounds, and pharmaceutical compositions thereof.
    Type: Grant
    Filed: June 7, 2022
    Date of Patent: April 15, 2025
    Assignee: Nuvalent, Inc.
    Inventors: Joshua Courtney Horan, Xinxing Tang, Scot Richard Mente, Henry Efrem Pelish, Matthew D. Shair, Anupong Tangpeerachaikul
  • METHODS OF TREATING SOLID TUMOR USING HETEROAROMATIC MACROCYCLIC ETHER COMPOUNDS
    Publication number: 20240398768
    Abstract: Provided herein are methods of using a heteroaromatic macrocyclic ether compound (e.g., Compound 1), or a stereoisomer, or a mixture of stereoisomers thereof, or a pharmaceutically acceptable salt thereof, for treating, preventing or managing solid tumor.
    Type: Application
    Filed: September 30, 2022
    Publication date: December 5, 2024
    Inventors: Amit M. DESHPANDE, Darlene NOCI, Henry Efrem PELISH, James R. PORTER, John R. SOGLIA, Anupong TANGPEERACHAIKUL, Christopher Durant TURNER, Michael MEYERS
  • HETEROAROMATIC MACROCYCLIC ETHER CHEMOTHERAPEUTIC AGENTS
    Publication number: 20240352037
    Abstract: Disclosed are heterocyclic heteroaromatic macrocyclic ether compounds, pharmaceutically acceptable salts of the compounds and pharmaceutical compositions thereof. The disclosure further relates to methods of treating or preventing cancer using the heterocyclic heteroaromatic macrocyclic ether compounds, pharmaceutically acceptable salts of the compounds and pharmaceutical compositions thereof.
    Type: Application
    Filed: June 17, 2024
    Publication date: October 24, 2024
    Inventors: Joshua Courtney Horan, Xinxing Tang, Scot Richard Mente, Henry Efrem Pelish, Matthew D. Shair, Anupong Tangpeerachaikul
  • AMINO-SUBSTITUTED HETEROCYCLES FOR TREATING CANCERS WITH EGFR MUTATIONS
    Publication number: 20240327435
    Abstract: Disclosed are amino-substituted heteroaromatic compounds such as 4-amino-quinazolines, pharmaceutically acceptable salts of the compounds, and pharmaceutical compositions thereof. Also disclosed are methods of treating or preventing cancer using the amino-substituted heteroaromatic compounds, pharmaceutically acceptable salts of the compounds, and pharmaceutical compositions thereof.
    Type: Application
    Filed: May 16, 2024
    Publication date: October 3, 2024
    Inventors: Kristin Lynne Andrews, Baudouin Gerard, Joshua Courtney Horan, Scot Richard Mente, Henry Efrem Pelish, Matthew D. Shair, Yuting Sun, Anupong Tangpeerachaikul
  • Heteroaromatic macrocyclic ether chemotherapeutic agents
    Patent number: 12054498
    Abstract: Disclosed are heterocyclic heteroaromatic macrocyclic ether compounds of Formula (I): pharmaceutically acceptable salts of the compounds and pharmaceutical compositions thereof. The disclosure further relates to methods of treating or preventing cancer using the heterocyclic heteroaromatic macrocyclic ether compounds, pharmaceutically acceptable salts of the compounds and pharmaceutical compositions thereof.
    Type: Grant
    Filed: June 7, 2022
    Date of Patent: August 6, 2024
    Assignee: NUVALENT, INC.
    Inventors: Joshua Courtney Horan, Xinxing Tang, Scot Richard Mente, Henry Efrem Pelish, Matthew D. Shair, Anupong Tangpeerachaikul
  • Amino-substituted heteroaryls for treating cancers with EGFR mutations
    Patent number: 12037346
    Abstract: Disclosed are amino-substituted heteroaromatic compounds such as a compound of Formula (I): pharmaceutically acceptable salts of the compounds, and pharmaceutical compositions thereof. Also disclosed are methods of treating or preventing cancer using the amino-substituted heteroaromatic compounds, pharmaceutically acceptable salts of the compounds, and pharmaceutical compositions thereof.
    Type: Grant
    Filed: April 12, 2022
    Date of Patent: July 16, 2024
    Assignee: Nuvalent, Inc.
    Inventors: Kristin Lynne Andrews, Baudouin Gerard, Joshua Courtney Horan, Scot Richard Mente, Henry Efrem Pelish, Matthew D. Shair, Yuting Sun, Anupong Tangpeerachaikul
  • Heteroaromatic macrocyclic ether chemotherapeutic agents
    Patent number: 11667649
    Abstract: Disclosed are heterocyclic heteroaromatic macrocyclic ether compounds, pharmaceutically acceptable salts of the compounds and pharmaceutical compositions thereof. Also disclosed are methods of treating or preventing cancer using the heterocyclic heteroaromatic macrocyclic ether compounds, pharmaceutically acceptable salts of the compounds, and pharmaceutical compositions thereof.
    Type: Grant
    Filed: November 11, 2021
    Date of Patent: June 6, 2023
    Assignee: Nuvalent, Inc.
    Inventors: Joshua Courtney Horan, Xinxing Tang, Scot Richard Mente, Henry Efrem Pelish, Matthew D. Shair, Anupong Tangpeerachaikul
  • HETEROAROMATIC MACROCYCLIC ETHER CHEMOTHERAPEUTIC AGENTS
    Publication number: 20230107663
    Abstract: Disclosed are heterocyclic heteroaromatic macrocyclic ether compounds, pharmaceutically acceptable salts of the compounds and pharmaceutical compositions thereof. The disclosure further relates to methods of treating or preventing cancer using the heterocyclic heteroaromatic macrocyclic ether compounds, pharmaceutically acceptable salts of the compounds and pharmaceutical compositions thereof.
    Type: Application
    Filed: June 7, 2022
    Publication date: April 6, 2023
    Inventors: Joshua Courtney Horan, Xinxing Tang, Scot Richard Mente, Henry Efrem Pelish, Matthew D. Shair, Anupong Tangpeerachaikul
  • HETEROAROMATIC MACROCYCLIC ETHER CHEMOTHERAPEUTIC AGENTS
    Publication number: 20230076627
    Abstract: Disclosed are heterocyclic heteroaromatic macrocyclic ether compounds, pharmaceutically acceptable salts of the compounds and pharmaceutical compositions thereof. Also disclosed are methods of treating or preventing cancer using the heterocyclic heteroaromatic macrocyclic ether compounds, pharmaceutically acceptable salts of the compounds, and pharmaceutical compositions thereof.
    Type: Application
    Filed: June 7, 2022
    Publication date: March 9, 2023
    Inventors: Joshua Courtney Horan, Xinxing Tang, Scot Richard Mente, Henry Efrem Pelish, Matthew D. Shair, Anupong Tangpeerachaikul
  • Heteroaromatic macrocyclic ether chemotherapeutic agents
    Patent number: 11542278
    Abstract: Disclosed are heterocyclic heteroaromatic macrocyclic ether compounds of Formula (I): pharmaceutically acceptable salts of the compounds and pharmaceutical compositions thereof. The disclosure further relates to methods of treating or preventing cancer using the heterocyclic heteroaromatic macrocyclic ether compounds, pharmaceutically acceptable salts of the compounds and pharmaceutical compositions thereof.
    Type: Grant
    Filed: October 29, 2021
    Date of Patent: January 3, 2023
    Assignee: Nuvalent, Inc.
    Inventors: Joshua Courtney Horan, Xinxing Tang, Scot Richard Mente, Henry Efrem Pelish, Matthew D. Shair, Anupong Tangpeerachaikul
  • AMINO-SUBSTITUTED HETEROCYCLES FOR TREATING CANCERS WITH EGFR MUTATIONS
    Publication number: 20220363696
    Abstract: Disclosed are amino-substituted heteroaromatic compounds such as 4-amino-quinazolines, pharmaceutically acceptable salts of the compounds, and pharmaceutical compositions thereof. Also disclosed are methods of treating or preventing cancer using the amino-substituted heteroaromatic compounds, pharmaceutically acceptable salts of the compounds, and pharmaceutical compositions thereof.
    Type: Application
    Filed: April 12, 2022
    Publication date: November 17, 2022
    Inventors: Kristin Lynne Andrews, Baudouin Gerard, Joshua Courtney Horan, Scot Richard Mente, Henry Efrem Pelish, Matthew D. Shair, Yuting Sun, Anupong Tangpeerachaikul
  • HETEROAROMATIC MACROCYCLIC ETHER CHEMOTHERAPEUTIC AGENTS
    Publication number: 20220340586
    Abstract: Disclosed are heterocyclic heteroaromatic macrocyclic ether compounds, pharmaceutically acceptable salts of the compounds and pharmaceutical compositions thereof Also disclosed are methods of treating or preventing cancer using the heterocyclic heteroaromatic macrocyclic ether compounds, pharmaceutically acceptable salts of the compounds, and pharmaceutical compositions thereof.
    Type: Application
    Filed: November 11, 2021
    Publication date: October 27, 2022
    Inventors: Joshua Courtney Horan, Xinxing Tang, Scot Richard Mente, Henry Efrem Pelish, Matthew D. Shair, Anupong Tangpeerachaikul
  • HETEROAROMATIC MACROCYCLIC ETHER CHEMOTHERAPEUTIC AGENTS
    Publication number: 20220098212
    Abstract: Disclosed are heterocyclic heteroaromatic macrocyclic ether compounds, pharmaceutically acceptable salts of the compounds and pharmaceutical compositions thereof Also disclosed are methods of treating or preventing cancer using the heterocyclic heteroaromatic macrocyclic ether compounds, pharmaceutically acceptable salts of the compounds, and pharmaceutical compositions thereof.
    Type: Application
    Filed: November 11, 2021
    Publication date: March 31, 2022
    Inventors: Joshua Courtney Horan, Xinxing Tang, Scot Richard Mente, Henry Efrem Pelish, Matthew D. Shair, Anupong Tangpeerachaikul